Targanta Therapeutics

20 August 2009

Dr Eric Abadie
European Medicines Agency
7 Westferry Circus
Canary Wharf
London
E14 4HB

Dear Dr Abadie,

**Re: RAMVOCID (oritavancin diphosphate)**
**Withdrawal of the Marketing Authorisation Application for Ramvocid® (oritavancin diphosphate) 100 mg powder for solution for infusion**
**EMEA/H/C/001025/0000**

On February 26, 2009, Targanta Therapeutics Corporation (Targanta) was acquired as a wholly owned subsidiary of The Medicines Company (MDCO). Key members of the oritavancin development team were retained in Indianapolis and Montreal, and, along with selected MDCO personnel, have formed the Anti-Infective Innovation Unit (AI/IU) to continue the development of oritavancin for the treatment of patients with complicated skin and soft tissue infections (cSSTI) and subsequent indications.

I would like to inform you that, at this point in time, Targanta has made the decision to withdraw the application for Marketing Authorisation of RAMVOCID, oritavancin diphosphate, 100mg powder for solution for infusion, which was intended to be used for the treatment of cSSTI.

This withdrawal is based on the following reason:

- the CHMP considers that the data provided do not allow the committee to conclude on a positive benefit risk balance

At this time there are no ongoing clinical trials with oritavancin.

Targanta is committed to the development of oritavancin for the treatment of patients with cSSTI and is exploring development opportunities for additional dose regimens and indications.

**Targanta Netherlands B.V., Naritaweg 165, Telestone 8, 1043BW Amsterdam, The Netherlands**
**Tel: + 31 20 572 2300, Fax: + 31 20 572 2650**

Targanta Therapeutics

Targanta reserves the right to make future submissions at a future date in this or other therapeutic indication(s).

Targanta (The Medicines Company) agrees for this letter to be published on the EMEA website.

Yours sincerely

**Targanta Netherlands B.V., Naritaweg 165, Telestone 8, 1043BW Amsterdam, The Netherlands**
**Tel: + 31 20 572 2300, Fax: + 31 20 572 2650**